THE COST-EFFECTIVENESS OF SECOND-LINE CRIZOTINIB IN EML4-ALK REARRANGED ADVANCED NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Graham, Donna M. [1 ]
Djalalov, Sandjar [2 ]
Beca, Jaclyn [2 ]
Hoch, Jeffrey [3 ]
Tsao, Ming S. [4 ]
Cutz, Jc [5 ]
Leighl, Natasha [1 ]
机构：
[1] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, East Melbourne, Vic, Australia
[2] Canc Care Ontario, Pharmacoecon Res Unit, Toronto, ON, Canada
[3] Canc Care Ontarior Pharmacoecon Unit, Toronto, ON, Canada
[4] Princess Margaret Canc Ctr, Dept Pathol, East Melbourne, Vic, Australia
[5] McMaster Univ, Hamilton, ON L8S 4L8, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
cost-effectiveness; ALK-rearrangement; Crizotinib; advanced non-small cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.24-037
引用
收藏
页码：S1317 / S1318
页数：2
相关论文
共 50 条
  • [21] Analysis of EML4-ALK rearrangement in non-small cell lung cancer in Argentina
    Verzura, Maria
    Batagelj, Emilio
    Bagnes, Claudia
    Martin, Claudio
    Enrico, Diego
    Richardet, Eduardo
    De la Iglesia, Paola
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2018, 34 : 77 - 81
  • [22] Targeting EML4-ALK driven non-small cell lung cancer (NSCLC)
    Moran, Teresa
    Quiroga, Vanesa
    Llanos Gil, Maria de Los
    Vila, Laia
    Pardo, Nuria
    Carcereny, Enric
    Capdevila, Laia
    Munoz-Marmol, Ana M.
    Rosell, Rafael
    TRANSLATIONAL LUNG CANCER RESEARCH, 2013, 2 (02) : 128 - 141
  • [23] EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer
    de Mello, Ramon Andrade
    Liu, Davi J. J.
    Aguiar, Pedro N., Jr.
    Tadokoro, Hakaru
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2016, 11 (04) : 393 - 400
  • [24] COST-EFFECTIVENESS OF THE SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Chang, C. W.
    Lang, H. C.
    VALUE IN HEALTH, 2019, 22 : S165 - S166
  • [25] COST-EFFECTIVENESS OF NIVOLUMAB VS. DOCETAXEL AS SECOND-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Shah, S.
    Matthews, S. E.
    Sarasani, S.
    Noel, S.
    Blanchette, C. M.
    VALUE IN HEALTH, 2016, 19 (07) : A732 - A732
  • [26] COST-EFFECTIVENESS OF CRIZOTINIB FOR SECOND AND THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ECUADOR
    Freire, V
    Cabezas, M.
    Salcedo, E.
    Albert, A.
    VALUE IN HEALTH, 2018, 21 : S30 - S31
  • [27] COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB IN METASTATIC ALK plus NON-SMALL CELL LUNG CANCER (NSCLC)
    Montero, Alberto J.
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1211 - S1212
  • [28] Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement:a case report
    Ling Zhang
    Yunxia Li
    Shaohong Zhang
    Chen Gao
    Keke Nie
    Youxin Ji
    Cancer Biology & Medicine, 2018, (02) : 178 - 181
  • [29] Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report
    Zhang, Ling
    Li, Yunxia
    Zhang, Shaohong
    Gao, Chen
    Nie, Keke
    Ji, Youxin
    CANCER BIOLOGY & MEDICINE, 2018, 15 (02) : 178 - 181
  • [30] Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement:a case report
    Ling Zhang
    Yunxia Li
    Shaohong Zhang
    Chen Gao
    Keke Nie
    Youxin Ji
    Cancer Biology & Medicine, 2018, 15 (02) : 178 - 181
12345